Advertisement

Gene Therapy in Malignancies: Development and Clinical Applications of Autologous Tumour Vaccines

  • J. I. Drayer
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 32)

Abstract

Various applications of therapeutically active cancer vaccines have recently been reviewed by Subiza et al. [1]. In their opinion, concepts and tools related to such therapies are more clear than ever before and clinical results are encouraging. Accompanying editorials express somewhat contrasting views. In one editorial the need is expressed for a combination of antigen-specific effect targeting the immune reaction to tumour plus a systemic immuno- or endocrine-modulating effect to treat cancer [2], and in the potential of the other producing progression or only temporary benefit following vaccine therapy [3].

Keywords

Renal Cell Carcinoma Cancer Vaccine Cell Dose Active Immunotherapy Irradiate Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Subiza JL, Cifuentes L, Medina MT. Prospects in cancer vaccines. Cancer J 1995; 8:293–98.Google Scholar
  2. 2.
    Fridman WH. Cancer vaccines — Myth or reality? Cancer J 1995;8:188–90.Google Scholar
  3. 3.
    Prehn RT. On the probability of effective anticancer vaccines. Cancer J 1995;8:284–85.Google Scholar
  4. 4.
    Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci 1993;90: 3539–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Berns A, Cohen L, Donehower RC. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with renal cell carcinoma. Hum Gene Ther 1996;6:347–68.CrossRefGoogle Scholar
  6. 6.
    Simons J, Jaffee EM, Weber C, et al. Bioactivity of human GM-CSF gene transfer in autologous irradiated renal cell carcinoma vaccines. J Clin Oncol 1997 (in press).Google Scholar
  7. 7.
    Pardoll DM. GM-CSF transfected autologous RC vaccine. Presented at the NCI-EORTC Conference, March 1996, Amsterdam, The Netherlands.Google Scholar
  8. 8.
    Rankin E. Immunological effects of vaccination with autologous, GM-CSF transduced and irradiated tumor cells in patients with advanced melanoma. Presented at the NCI-EORTC Conference, March 1996, Amsterdam, The Netherlands.Google Scholar
  9. 9.
    Dranoff G. Granulocyte-macrophage colony stimulating factor based melanoma vaccines. Presented at the Molecular Medicine Society Conference, May 1996, Washington DC.Google Scholar
  10. 10.
    Morton DL, Barth A. Vaccine therapy for malignanat melanoma. CA Cancer J Clin 1996;46:225–44.PubMedCrossRefGoogle Scholar
  11. 11.
    Baltz JK. Vaccines in the treatment of cancer. Am J Health Syst Pharm 1995;52: 2574–85.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • J. I. Drayer

There are no affiliations available

Personalised recommendations